Evidence map›Paper›PMID 37509661›Full record

ArticleBiomedicines2023

A Biosafety Study of Human Umbilical Cord Blood Mononuclear Cells Transduced with Adenoviral Vector Carrying Human Vascular Endothelial Growth Factor cDNA In Vitro.

Ilnur I Salafutdinov, Dilara Z Gatina, Maria I Markelova, Ekaterina E Garanina, Sergey Yu Malanin, Ilnaz M Gazizov, Andrei A Izmailov, Albert A Rizvanov, Rustem R Islamov, András Palotás and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Neural Correlates and Molecular Mechanisms of Memory and Learning.International journal of molecular sciences · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Ilnur I SalafutdinovDepartment of Histology, Cytology and Embryology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0001-6988-0673
Dilara Z GatinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0002-2063-8314
Maria I MarkelovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0001-7445-2091
Ekaterina E GaraninaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Sergey Yu MalaninInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Ilnaz M GazizovDepartment of Histology, Cytology and Embryology, Kazan State Medical University, Kazan 420012, Russia.
Andrei A IzmailovDepartment of Histology, Cytology and Embryology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-8128-4636
Albert A RizvanovInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0002-9427-5739
Rustem R IslamovDepartment of Histology, Cytology and Embryology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-6632-4636
András PalotásInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Zufar Z SafiullovDepartment of Histology, Cytology and Embryology, Kazan State Medical University, Kazan 420012, Russia.
Kazan Federal University · RUKazan State Medical University · RU

Funding

Russian Science Foundation 19-75-10030
6 · The paper itself

Abstract

The biosafety of gene therapy remains a crucial issue for both the direct and cell-mediated delivery of recombinant cDNA encoding biologically active molecules for the pathogenetic correction of congenital or acquired disorders. The diversity of vector systems and cell carriers for the delivery of therapeutic genes revealed the difficulty of developing and implementing a safe and effective drug containing artificial genetic material for the treatment of human diseases in practical medicine. Therefore, in this study we assessed changes in the transcriptome and secretome of umbilical cord blood mononuclear cells (UCB-MCs) genetically modified using adenoviral vector (Ad5) carrying cDNA encoding human vascular endothelial growth factor (VEGF165) or reporter green fluorescent protein (GFP). A preliminary analysis of UCB-MCs transduced with Ad5-VEGF165 and Ad5-GFP with MOI of 10 showed efficient transgene expression in gene-modified UCB-MCs at mRNA and protein levels. The whole transcriptome sequencing of native UCB-MCs, UCB-MC+Ad5-VEGF165, and UCB-MC+Ad5-GFP demonstrated individual sample variability rather than the effect of Ad5 or the expression of recombinant

Indexed as

biosafetycord blood stem cell transplantationgenetic therapygenetic vectorssecretometranscriptomevascular endothelial growth factor A

Identifiers

PMID37509661
PMCPMC10377014
OpenAlexW4384827562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.